WO1999062944A3 - Protein oligomer compositions comprising endostatin protein and methods of using the same - Google Patents

Protein oligomer compositions comprising endostatin protein and methods of using the same Download PDF

Info

Publication number
WO1999062944A3
WO1999062944A3 PCT/US1999/012278 US9912278W WO9962944A3 WO 1999062944 A3 WO1999062944 A3 WO 1999062944A3 US 9912278 W US9912278 W US 9912278W WO 9962944 A3 WO9962944 A3 WO 9962944A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
methods
endostatin
oligomer compositions
same
Prior art date
Application number
PCT/US1999/012278
Other languages
French (fr)
Other versions
WO1999062944A2 (en
Inventor
Kashi Javaherian
M Judah Folkman
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Priority to JP2000552154A priority Critical patent/JP2002517186A/en
Priority to AU44140/99A priority patent/AU4414099A/en
Priority to CA002331370A priority patent/CA2331370A1/en
Priority to KR1020007013734A priority patent/KR20010052566A/en
Publication of WO1999062944A2 publication Critical patent/WO1999062944A2/en
Publication of WO1999062944A3 publication Critical patent/WO1999062944A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Protein oligomer compositions comprising endostatin protein are provided as well as methods of using the protein oligomer compositions to disrupt tubule formation and inhibit tumorigenesis. The compositions of the present invention constitute a new class of scatter factors and specifically include endostatin protein dimers and trimers, and optionally include metal ions such as zinc.
PCT/US1999/012278 1998-06-03 1999-06-03 Protein oligomer compositions comprising endostatin protein and methods of using the same WO1999062944A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000552154A JP2002517186A (en) 1998-06-03 1999-06-03 Protein oligomer compositions containing endostatin proteins and methods of using the same
AU44140/99A AU4414099A (en) 1998-06-03 1999-06-03 Protein oligomer compositions comprising endostatin protein and methods of usingthe same
CA002331370A CA2331370A1 (en) 1998-06-03 1999-06-03 Protein oligomer compositions comprising endostatin protein and methods of using the same
KR1020007013734A KR20010052566A (en) 1998-06-03 1999-06-03 Protein oligomer compositions comprising endostatin protein and methods of using the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8789098P 1998-06-03 1998-06-03
US9239398P 1998-07-10 1998-07-10
US9879098P 1998-09-01 1998-09-01
US60/7098,790 1998-09-01
US60/087,890 1998-09-01
US60/092,393 1998-09-01

Publications (2)

Publication Number Publication Date
WO1999062944A2 WO1999062944A2 (en) 1999-12-09
WO1999062944A3 true WO1999062944A3 (en) 2000-04-06

Family

ID=27375776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012278 WO1999062944A2 (en) 1998-06-03 1999-06-03 Protein oligomer compositions comprising endostatin protein and methods of using the same

Country Status (5)

Country Link
JP (1) JP2002517186A (en)
KR (1) KR20010052566A (en)
AU (1) AU4414099A (en)
CA (1) CA2331370A1 (en)
WO (1) WO1999062944A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
CN100422332C (en) * 1998-08-25 2008-10-01 默克专利股份公司 Expression and export of angiostation and endostatin as immunofusins
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
JP2007525972A (en) 2003-08-29 2007-09-13 チルドレンズ メディカル センター コーポレーション Anti-angiogenic peptides from the N-terminus of endostatin
FR2898895B1 (en) * 2006-03-23 2012-04-06 Univ Reims Champagne Ardenne CYCLOPEPTIDE WITH ANTI-CANCER ACTIVITY DERIVED FROM TYPE IV COLLAGEN
BRPI0605212B8 (en) * 2006-12-12 2021-05-25 Univ Rio De Janeiro production process of dimerized or oligomerized endostatin, dimerized or oligomerized endostatin and pharmaceutical composition
US8586544B2 (en) 2008-04-04 2013-11-19 Procell Therapeutics Inc. Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
WO2015046554A1 (en) * 2013-09-30 2015-04-02 中外製薬株式会社 Method for producing antigen-binding molecule using modified helper phage
WO2016197018A1 (en) 2015-06-05 2016-12-08 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis
CN112236448A (en) 2018-04-17 2021-01-15 海德堡生物技术有限公司 Means and methods for treating angiogenesis, fibrosis and cancer related diseases with protein oligomers comprising NC-1-Fc

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202932A (en) * 1995-10-23 1998-12-23 儿童医学中心公司 Therapeutic antiangiogenic compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
S P OH ET AL.: "Isolation and sequnecing of cDNA for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of proteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 91, no. 10, 10 May 1994 (1994-05-10), NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US, pages 4229 - 4233, XP002127257, ISSN: 0027-8424 *
Y DING ET AL.: "Zinc-dependent dimers observed in crystals of human endostatin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 95, no. 18, 1 September 1998 (1998-09-01), NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US, pages 10443 - 10448, XP002127259, ISSN: 0027-8424 *
Y MURAGAKI ET AL.: "Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 92, no. 19, 12 September 1995 (1995-09-12), NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US, pages 8763 - 8767, XP002127258, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
KR20010052566A (en) 2001-06-25
CA2331370A1 (en) 1999-12-09
WO1999062944A2 (en) 1999-12-09
AU4414099A (en) 1999-12-20
JP2002517186A (en) 2002-06-18

Similar Documents

Publication Publication Date Title
WO1999062944A3 (en) Protein oligomer compositions comprising endostatin protein and methods of using the same
AU5439899A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as cetp inhibitors
WO2000025723A3 (en) Methods and compositions for the prevention of tolerance to medications
WO2002057293A3 (en) Modified zinc finger binding proteins
WO2000023464A3 (en) Zinc finger binding domains for gnn
WO2001076640A3 (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
AU1933500A (en) Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
CA2318398A1 (en) Novel peptides having biological activity
WO2000009553A3 (en) Antimicrobial peptides isolated from the skin of american frogs
WO2001034647A3 (en) Animal collagens and gelatins
WO1999052543A3 (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
AU3481899A (en) Blade holster assembly
AU1915399A (en) Cs-1 peptidomimetics, compositions and methods of using the same
AU1334800A (en) Oil resistant compositions
WO2004113528A3 (en) Isoforms of elf-5a: senescence-induced elf5a; wounding-induced elf-5a; growth elf-5a; and dhs
IL139604A0 (en) Novel peptides
AU4088097A (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans
AU5490099A (en) Manufacture of alpha-olefins
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
BG103320A (en) Method for the alkylating hindered sulphonamides
WO2002028432A3 (en) Stem cell-based methods for preventing and treating tumor
WO1998017827A3 (en) Compositions and methods using eukaryotic rad52
WO2000015625A3 (en) Methods of making dihydropyrone hiv protease inhibitors
WO1999061598A3 (en) Lentiviral vector compositions and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2331370

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 552154

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020007013734

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007013734

Country of ref document: KR

122 Ep: pct application non-entry in european phase
WWR Wipo information: refused in national office

Ref document number: 1020007013734

Country of ref document: KR